

USANA HEALTH SCIENCES INC  
Form 10-Q  
November 09, 2016  
[Table of Contents](#)

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended October 1, 2016

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number: 001-35024

---

**USANA HEALTH SCIENCES, INC.**

(Exact name of registrant as specified in its charter)

**Utah**  
(State or other jurisdiction  
of incorporation or organization)

**87-0500306**  
(I.R.S. Employer  
Identification No.)

---

**3838 West Parkway Blvd., Salt Lake City, Utah 84120**

(Address of principal executive offices, Zip Code)

---

**(801) 954-7100**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

The number of shares outstanding of the registrant's common stock as of November 4, 2016 was 12,193,500.

On October 25, 2016, the registrant declared a two-for-one stock split of its common stock that will be distributed in the form of a stock dividend on November 22, 2016 to shareholders of record as of November 14, 2016. Outstanding common stock data in future filings will be retrospectively adjusted to reflect the stock split.

---

Table of Contents

USANA HEALTH SCIENCES, INC.

FORM 10-Q

For the Quarterly Period Ended October 1, 2016

INDEX

	Page	
<b><u>PART I. FINANCIAL INFORMATION</u></b>		
<u>Item 1</u>	<u>Financial Statements (unaudited)</u>	
	<u>Condensed Consolidated Balance Sheets</u>	3
	<u>Condensed Consolidated Statements of Comprehensive Income</u>	4
	<u>Condensed Consolidated Statements of Stockholders' Equity</u>	5
	<u>Condensed Consolidated Statements of Cash Flows</u>	6
	<u>Notes to Condensed Consolidated Financial Statements</u>	7-14
<u>Item 2</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	15-25
<u>Item 3</u>	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	25
<u>Item 4</u>	<u>Controls and Procedures</u>	25
<b><u>PART II. OTHER INFORMATION</u></b>		
<u>Item 5</u>	<u>Other Information</u>	25
<u>Item 6</u>	<u>Exhibits</u>	26
		28
<u>Signatures</u>		

Table of Contents**PART I. FINANCIAL INFORMATION****Item 1. Financial Statements****USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED BALANCE SHEETS**

(in thousands, except par value)

(unaudited)

	As of January 2, 2016	As of October 1, 2016
<b>ASSETS</b>		
Current assets		
Cash and cash equivalents	\$ 143,210	\$ 134,543
Inventories	66,119	74,146
Prepaid expenses and other current assets	34,935	39,423
Total current assets	244,264	248,112
Property and equipment, net	87,982	103,916
Goodwill	17,432	17,138
Intangible assets, net	38,269	36,130
Deferred tax assets	9,844	15,404
Other assets	25,446	22,908
	\$ 423,237	\$ 443,608
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities		
Accounts payable	\$ 10,043	\$ 10,586
Line of credit - short term		1,200
Other current liabilities	121,369	116,648
Total current liabilities	131,412	128,434
Deferred tax liabilities	9,822	5,971
Other long-term liabilities	1,151	1,494
Stockholders' equity		
Common stock, \$0.001 par value; Authorized 50,000 shares, issued and outstanding 12,488 as of January 2, 2016 and 12,176 as of October 1, 2016	13	12

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Additional paid-in capital	69,740	68,938
Retained earnings	214,875	243,523
Accumulated other comprehensive income (loss)	(3,776)	(4,764)
Total stockholders' equity	280,852	307,709
	\$ 423,237	\$ 443,608

The accompanying notes are an integral part of these statements.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands, except per share data)

(unaudited)

	Quarter Ended		Nine Months Ended	
	October 3, 2015	October 1, 2016	October 3, 2015	October 1, 2016
Net sales	\$ 233,292	\$ 254,219	\$ 685,914	\$ 753,182
Cost of sales	41,048	44,979	119,501	133,869
Gross profit	192,244	209,240	566,413	619,313
Operating expenses:				
Associate incentives	101,521	112,816	304,751	335,541
Selling, general and administrative	52,757	60,591	155,137	176,986
Total operating expenses	154,278	173,407	459,888	512,527
Earnings from operations	37,966	35,833	106,525	106,786
Other income (expense):				
Interest income	367	338	753	1,099
Interest expense	(4)	(46)	(11)	(424)
Other, net	78	(24)	(219)	(684)
Other income (expense), net	441	268	523	(9)
Earnings before income taxes	38,407	36,101	107,048	106,777
Income taxes	12,798	6,003	36,343	28,618
Net earnings	\$ 25,609	\$ 30,098	\$ 70,705	\$ 78,159
Earnings per common share				
Basic	\$ 1.99	\$ 2.49	\$ 5.55	\$ 6.48
Diluted	\$ 1.92	\$ 2.40	\$ 5.35	\$ 6.24
Weighted average common shares outstanding				
Basic	12,852	12,089	12,747	12,056
Diluted	13,317	12,525	13,209	12,525
Comprehensive income:				
Net earnings	\$ 25,609	\$ 30,098	\$ 70,705	\$ 78,159

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Other comprehensive income (loss), net of tax:				
Foreign currency translation adjustment	(4,990)	(341)	(6,374)	(2,643)
Tax benefit (expense) related to foreign currency translation adjustment	1,831	(515)	2,355	1,655
Other comprehensive income (loss), net of tax	(3,159)	(856)	(4,019)	(988)
Comprehensive income	\$ 22,450	\$ 29,242	\$ 66,686	\$ 77,171

The accompanying notes are an integral part of these statements.



Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY

Nine Months Ended October 1, 2016

(in thousands)

(unaudited)

	Common Stock Shares	Value	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total
Balance at January 2, 2016	12,488	\$ 13	\$ 69,740	\$ 214,875	\$ (3,776)	\$ 280,852
Cumulative-effect of accounting change			934	(601)		333
Balance at January 2, 2016, as adjusted	12,488	\$ 13	\$ 70,674	\$ 214,274	\$ (3,776)	\$ 281,185
Net earnings				78,159		78,159
Other comprehensive income (loss), net of tax					(988)	(988)
Equity-based compensation expense			13,963			13,963
Common stock repurchased and retired	(553)	(1)	(15,699)	(48,910)		(64,610)
Common stock issued under equity award plans	241					
Balance at October 1, 2016	12,176	\$ 12	\$ 68,938	\$ 243,523	\$ (4,764)	\$ 307,709

The accompanying notes are an integral part of these statements.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

	Nine Months Ended	
	October 3, 2015	October 1, 2016
Cash flows from operating activities		
Net earnings	\$ 70,705	\$ 78,159
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities		
Depreciation and amortization	7,284	9,930
(Gain) loss on sale of property and equipment	1	55
Equity-based compensation expense	6,952	13,963
Excess tax benefits from equity-based payment arrangements	(9,739)	
Deferred income taxes	(1,993)	(2,249)
Changes in operating assets and liabilities:		
Inventories	(18,432)	(7,922)
Prepaid expenses and other assets	(565)	(12,179)
Income tax payable related to tax benefit from equity award activity	9,587	
Accounts payable	1,868	597
Other liabilities	8,849	1,386
Net cash provided by (used in) operating activities	74,517	81,740
Cash flows from investing activities		
Additions to notes receivable	(1,579)	(4)
Receipts on notes receivable		605
Proceeds from sale of property and equipment	182	3
Purchases of property and equipment	(16,468)	(26,047)
Net cash provided by (used in) investing activities	(17,865)	(25,443)
Cash flows from financing activities		
Excess tax benefits from equity-based payment arrangements	9,739	
Repurchase of common stock		(64,610)
Borrowings on line of credit		73,700
Payments on line of credit		(72,500)
Deferred debt issuance costs		(250)
Net cash provided by (used in) financing activities	9,739	(63,660)
Effect of exchange rate changes on cash and cash equivalents	(3,322)	(1,304)
Net increase (decrease) in cash and cash equivalents	63,069	(8,667)

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Cash and cash equivalents, beginning of period	111,126	143,210
Cash and cash equivalents, end of period	\$ 174,195	\$ 134,543
Supplemental disclosures of cash flow information		
Cash paid during the period for:		
Interest	\$ 11	\$ 317
Income taxes	18,918	41,114
Non-cash investing activities:		
Credits on notes receivable	466	1,142
Accrued purchases of property and equipment	1,906	1,763

The accompanying notes are an integral part of these statements.

Table of Contents

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(in thousands, except per share data)**

**(unaudited)**

**NOTE A ORGANIZATION, CONSOLIDATION, AND BASIS OF PRESENTATION**

USANA Health Sciences, Inc. develops and manufactures high-quality nutritional and personal care products that are sold internationally through a global network marketing system, which is a form of direct selling. The Consolidated Financial Statements include the accounts and operations of USANA Health Sciences, Inc. and its wholly-owned subsidiaries (collectively, the Company or USANA ) in two geographic regions: Asia Pacific, and Americas and Europe. Asia Pacific is further divided into three sub-regions: Greater China, Southeast Asia Pacific, and North Asia. Greater China includes Hong Kong, Taiwan and China; Southeast Asia Pacific includes Australia, New Zealand, Singapore, Malaysia, the Philippines, Thailand, and Indonesia; North Asia includes Japan, and South Korea. Americas and Europe includes the United States, Canada, Mexico, Colombia, the United Kingdom, France, Belgium, and the Netherlands. All intercompany accounts and transactions have been eliminated in consolidation.

The condensed consolidated balance sheet as of January 2, 2016, derived from audited consolidated financial statements, and the unaudited interim consolidated financial information of the Company have been prepared in accordance with Article 10 of Regulation S-X promulgated by the Securities and Exchange Commission. Certain information and footnote disclosures that are normally included in financial statements that have been prepared in accordance with accounting principles generally accepted in the United States of America ( U.S. GAAP ) have been condensed or omitted pursuant to such rules and regulations. The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. In the opinion of management, the accompanying interim condensed consolidated financial information contains all adjustments, consisting only of normal recurring adjustments that are necessary to state fairly the Company's financial position as of October 1, 2016 and results of operations for the quarters and nine months ended October 3, 2015 and October 1, 2016.

The interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto that are included in the Company's Annual Report on Form 10-K for the year ended January 2, 2016. The results of operations for the nine months ended October 1, 2016, may not be indicative of the results that may be expected for the fiscal year 2016 ending December 31, 2016.

On October 25, 2016, the Company declared a two-for-one stock split of its common stock that will be distributed in the form of a stock dividend on November 22, 2016 to shareholders of record as of November 14, 2016. This stock dividend will double the number of shares outstanding but will not affect the number of authorized shares of the Company or the par value of the common stock. All existing stock option agreements provide that the number of shares of common stock and the respective exercise price covered by each outstanding option agreement be proportionately adjusted for a stock split or similar event.

**Recent Accounting Pronouncements**

In May 2014, the Financial Accounting Standards Board ( FASB ) issued an Accounting Standard Update ( ASU ) No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 includes a five-step process by which entities will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which an entity expects to be entitled in exchange for those goods or services. The standard also will require enhanced disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. In July 2015, the FASB announced a decision to defer the effective date of this ASU. ASU 2014-09 is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted for annual and interim reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact ASU 2014-09 will have on its consolidated financial statements.

Table of Contents

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(in thousands, except per share data)**

**(unaudited)**

**NOTE A ORGANIZATION, CONSOLIDATION, AND BASIS OF PRESENTATION - CONTINUED**

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). ASU 2016-02 is intended to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Additionally, the ASU will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases, including qualitative and quantitative requirements. The update requires lessees to apply a modified retrospective approach for recognition and disclosure, beginning with the earliest period presented. The ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact ASU 2016-02 will have on its consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 was issued as part of the FASB's simplification initiative aimed at reducing costs and complexity while maintaining or improving the usefulness of financial information. This update involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, forfeitures, statutory tax withholding requirements, and classification in the statement of cash flows. This ASU is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period, and the entity must adopt all of the amendments in the same period. The Company elected to early adopt ASU 2016-09 during the quarter ended April 2, 2016.

The impact of the early adoption of this standard increased net earnings by approximately \$6,491 and \$7,316 for the quarter and nine months ended October 1, 2016, respectively. Diluted earnings per share, benefited the quarter and nine months ended October 1, 2016, by \$0.50 and \$0.52, respectively.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)

## NOTE B FAIR VALUE MEASURES

The Company measures at fair value certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and best use of the asset or liability. The levels of the fair value hierarchy are:

- Level 1 inputs are quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement date.
- Level 2 inputs are from other than quoted market prices included in Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3 inputs are unobservable and are used to measure fair value in situations where there is little, if any, market activity for the asset or liability at the measurement date.

As of the dates indicated, the following financial assets and liabilities were measured at fair value on a recurring basis using the type of inputs shown:

	Fair Value Measurements Using			
	January 2, 2016	Level 1	Inputs Level 2	Level 3
Money market funds included in cash equivalents	\$ 14,460	\$ 14,460	\$	\$
Foreign currency contracts included in prepaid expenses and other current assets	33		33	
	\$ 14,493	\$ 14,460	\$ 33	\$
	Fair Value Measurements Using			
	October 1, 2016	Level 1	Inputs Level 2	Level 3

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Money market funds included in cash equivalents	\$	44,541	\$	44,541	\$	\$
Foreign currency contracts included in prepaid expenses and other current assets		179				179
	\$	44,720	\$	44,541	\$	179
					\$	



Table of Contents**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(in thousands, except per share data)****(unaudited)****NOTE B FAIR VALUE MEASURES - CONTINUED**

There were no transfers of financial assets or liabilities between levels of the fair value hierarchy for the periods indicated.

The majority of the Company's non-financial assets, which include goodwill, intangible assets, and property and equipment, are not required to be carried at fair value on a recurring basis. However, if certain triggering events occur (or tested at least annually for goodwill and indefinite-lived intangibles) such that a non-financial asset is required to be evaluated for impairment, an impairment charge is recorded to reduce the carrying value to the fair value, if the carrying value exceeds the fair value. At January 2, 2016 and October 1, 2016, there were no non-financial assets measured at fair value on a non-recurring basis.

The Company's financial instruments include cash equivalents, accounts receivable, restricted cash, notes receivable, and accounts payable. The recorded values of cash equivalents, accounts receivable, restricted cash, and accounts payable approximate their fair values, based on their short-term nature. The carrying value of the notes receivable approximate fair value because the variable interest rates in the notes reflect current market rates.

**NOTE C INVENTORIES**

Inventories consist of the following:

	<b>January 2, 2016</b>	<b>October 1, 2016</b>
Raw materials	\$ 22,529	\$ 27,388
Work in progress	8,701	9,482
Finished goods	34,889	37,276
	<b>\$ 66,119</b>	<b>\$ 74,146</b>

**NOTE D INTANGIBLE ASSETS**

The Company performed its annual goodwill impairment test during the third quarter of 2016. The Company performed a qualitative assessment of each reporting unit and determined that it was not more-likely-than-not that the fair value of each reporting unit was less than its carrying amount. As a result, the two-step goodwill impairment test was not required and no impairments of goodwill were recognized.

The Company performed its annual indefinite-lived intangible asset impairment test during the third quarter of 2016. The Company performed a qualitative assessment of the indefinite-lived intangible asset and determined that it was not more-likely-than-not that the fair value of the indefinite-lived intangible asset was less than the carrying amount. As a result, the quantitative impairment test was not required and no impairment was recognized.

#### **NOTE E OTHER ASSETS**

Other assets consists primarily of a secured loan to a third-party supplier of the Company's nutrition bars and land use rights related to a production facility under development in China.

The Company has extended non-revolving credit to its supplier of nutrition bars to allow them to acquire equipment that is necessary to manufacture the USANA nutrition bars. This relationship provides improved supply chain stability for USANA and creates a mutually beneficial relationship between the parties. Notes receivable are valued at their unpaid principal balance plus any accrued but unpaid interest, which approximates fair value. Interest accrues at an annual interest rate of LIBOR plus 400 basis points. The note has a maturity date of February 1, 2024 and will be repaid by a combination of cash payments and credits for the manufacture of USANA's nutrition bars. There is no prepayment penalty. Notes receivable from this supplier as of January 2, 2016, and October 1, 2016 were \$8,339 and \$7,099, respectively.

This third-party supplier is considered to be a variable interest entity; however, the Company is not the primary beneficiary due to the inability to direct the activities that most significantly affect the third-party supplier's economic performance. Additionally, the Company does not absorb a majority of the third-party supplier's expected losses or returns. Consequentially, the financial information of the third-party supplier is not consolidated. The maximum exposure to loss as a result of the Company's involvement with the third-party supplier is limited to the carrying value of the note receivable due from the third-party supplier.

The Company is building a state-of-the-art manufacturing and production facility in China, which is expected to become fully operational by the end of 2016. As part of this project, land use rights totaling \$7,053, and \$6,865 as of January 2, 2016 and October 1, 2016, respectively, have been purchased and are being amortized over 50 years.

Table of Contents

**USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(in thousands, except per share data)**

**(unaudited)**

**NOTE F LINE OF CREDIT**

On February 19, 2016, the Company entered into an Amended and Restated Credit Agreement ( Credit Agreement ), with Bank of America, which extends the term of the Credit Agreement to April 27, 2021. The Credit Agreement also increases the amount the Company may borrow under the credit facility from \$75,000 to up to \$125,000, through October 31, 2016. On November 1, 2016, the amount the Company may borrow will revert to \$75,000 for the remainder of the agreement. The only other modification to the Credit Agreement was an increase to the Company's consolidated rolling four-quarter adjusted EBITDA covenant from \$60,000 to equal to or greater than \$100,000.

Interest is computed based on the bank's Prime Rate or LIBOR, adjusted by features specified in the Credit Agreement. The collateral for this line of credit is the pledge of the capital stock of certain subsidiaries of the Company, set forth in a separate pledge agreement with the bank. Part of the credit agreement is that any existing bank guarantees are considered a reduction of the overall availability of credit and part of the covenant calculation. This resulted in a \$4,153, and \$5,078 reduction in the available borrowing limit as of January 2, 2016 and October 1, 2016, respectively, due to existing normal course of business guarantees in certain markets.

At October 1, 2016 there was an outstanding balance of \$1,200. The Company will be required to pay any balance on this line of credit in full at the time of maturity in April 2021 unless the line of credit is replaced or terms are renegotiated.

**NOTE G CONTINGENCIES**

The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company records a liability when a particular contingency is probable and estimable. The Company has not accrued for any contingency at October 1, 2016 as the Company does not consider any contingency to be probable nor estimable. The Company faces contingencies that are reasonably possible to occur; however, they cannot currently be estimated. While complete assurance cannot be given to the outcome of these proceedings, management does not currently believe that any of these matters, individually or in the aggregate, will have a material adverse effect on the Company's financial condition, liquidity or results of operations.

In August 2014, a purported shareholder derivative lawsuit was filed in the Third Judicial District Court of Salt Lake County, State of Utah (James Robert Rawcliffe v. Robert Anciaux, et al.) against certain of the Company's directors and officers. The derivative complaint, which also names USANA as a nominal defendant but is asserted on USANA's behalf, contains claims of breach of fiduciary duty, waste of corporate assets and unjust enrichment against the defendant directors and officers in connection with certain equity awards granted by the Compensation

## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Committee of the Company's Board of Directors in February 2014. In October 2014, the Company filed a motion to dismiss the complaint and, in March 2015, the court granted that motion and dismissed the complaint without prejudice. In May 2015, the plaintiffs filed an appeal with the Utah Supreme Court. The Supreme Court remanded the Company's case to the Utah Court of Appeals. The plaintiff and the Company have each filed their appellate brief with the court and oral arguments have been scheduled to take place in January 2017. The Company believes that the claims in the complaint are without merit and will continue to vigorously defend this suit. The Company continues to believe, based on information currently available, that the final outcome of this suit will not have a material adverse effect on the Company's business, results of operations or consolidated financial position.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)

**NOTE H COMMON STOCK AND EARNINGS PER SHARE**

Basic earnings per share are based on the weighted-average number of shares outstanding for each period. Shares that have been repurchased and retired during the periods specified below have been included in the calculation of the number of weighted-average shares that are outstanding for the calculation of basic earnings per share based on the time they were outstanding in any period. Diluted earnings per common share are based on shares that are outstanding (computed under basic EPS) and on potentially dilutive shares. Shares that are included in the diluted earnings per share calculations under the treasury stock method include equity awards that are in-the-money but have not yet been exercised.

The following is a reconciliation of the numerator and denominator used to calculate basic earnings per share and diluted earnings per share for the periods indicated:

	Quarter Ended		Nine Months Ended	
	October 3, 2015	October 1, 2016	October 3, 2015	October 1, 2016
Net earnings available to common shareholders	\$ 25,609	\$ 30,098	\$ 70,705	\$ 78,159
Weighted average common shares outstanding - basic	12,852	12,089	12,747	12,056
Dilutive effect of in-the-money equity awards	465	436	462	469
Weighted average common shares outstanding - diluted	13,317	12,525	13,209	12,525
Earnings per common share from net earnings - basic	\$ 1.99	\$ 2.49	\$ 5.55	\$ 6.48
Earnings per common share from net earnings - diluted	\$ 1.92	\$ 2.40	\$ 5.35	\$ 6.24

Equity awards for the following shares were not included in the computation of diluted EPS due to the fact that their effect would be anti-dilutive:

Quarter Ended

Nine Months Ended

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

	October 3, 2015	October 1, 2016	October 3, 2015	October 1, 2016
	361	1,154	196	1,118

During the nine months ended October 1, 2016, the Company repurchased and retired 553 shares, for \$64,610, under the Company's share repurchase plan. The excess of the repurchase price over par value is allocated between additional paid-in capital and retained earnings on a pro-rata basis. The purchase of shares under this plan reduces the number of shares outstanding in the above calculations.

As of October 1, 2016, the remaining approved repurchase amount under the stock repurchase plan was \$35,390. There currently is no expiration date on the remaining approved repurchase amount and no requirement for future share repurchases.

Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)

## NOTE I SEGMENT INFORMATION

USANA operates as a direct selling company that develops, manufactures, and distributes high-quality nutritional and personal care products that are sold through a global network marketing system of independent distributors ( Associates ). As such, management aggregates its operating segments into one reportable segment as management believes that the Company's segments exhibit similar long-term financial performance and have similar economic characteristics. Performance for a region or market is evaluated based on sales. No single Associate accounted for 10% or more of net sales for the periods presented. The table below summarizes the approximate percentage of total product revenue that has been contributed by the Company's nutritional and personal care products for the periods indicated.

	Quarter Ended		Nine Months Ended	
	October 3, 2015	October 1, 2016	October 3, 2015	October 1, 2016
USANA® Nutritionals	80%	85%	81%	83%
USANA Foods	12%	8%	12%	10%
Sensé beautiful science®	7%	6%	6%	6%

Selected financial information for the Company is presented for two geographic regions: Asia Pacific, with three sub-regions under Asia Pacific, and Americas and Europe. Individual markets are categorized into these regions as follows:

- Asia Pacific
- Greater China Hong Kong, Taiwan and China(1)
- Southeast Asia Pacific Australia, New Zealand, Singapore, Malaysia, the Philippines, Thailand, and Indonesia(2)
- North Asia Japan and South Korea

- Americas and Europe United States, Canada, Mexico, Colombia, the United Kingdom, France, Belgium, and the Netherlands.

---

(1) The Company's business in China is that of BabyCare, its wholly-owned subsidiary.

(2) The Company commenced operations in Indonesia in the fourth quarter of 2015.



Table of Contents

## USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

(in thousands, except per share data)

(unaudited)

## NOTE I SEGMENT INFORMATION - CONTINUED

*Selected Financial Information*

Financial information by geographic region is presented for the periods indicated below:

	Quarter Ended		Nine Months Ended	
	October 3, 2015	October 1, 2016	October 3, 2015	October 1, 2016
Net Sales to External Customers				
Asia Pacific				
Greater China	\$ 112,323	\$ 124,470	\$ 325,942	\$ 373,308
Southeast Asia Pacific	45,936	54,351	137,308	154,335
North Asia	9,920	11,555	29,495	33,376
Asia Pacific Total	168,179	190,376	492,745	561,019
Americas and Europe	65,113	63,843	193,169	192,163
Consolidated Total	\$ 233,292	\$ 254,219	\$ 685,914	\$ 753,182

The following table provides further information on markets representing ten percent or more of consolidated net sales and long-lived assets, respectively:

	Quarter Ended		Nine Months Ended	
	October 3, 2015	October 1, 2016	October 3, 2015	October 1, 2016
Net sales:				
China	\$ 95,147	\$ 108,355	\$ 273,433	\$ 324,689
United States	\$ 37,325	\$ 34,352	\$ 107,112	\$ 101,245

As of  
January 2,                      October 1,

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

	2016	2016
Long-lived Assets:		
China	\$ 92,835	\$ 95,455
United States	\$ 57,797	\$ 64,415

Table of Contents

**Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

The following discussion and analysis of USANA's financial condition and results of operations is presented in six sections:

- Overview
- Customers
- Current Focus and Recent Developments
- Results of Operations
- Liquidity and Capital Resources
- Forward-Looking Statements and Certain Risks

This discussion and analysis should be read in conjunction with the Unaudited Condensed Consolidated Financial Statements and Notes thereto that are contained in this quarterly report, as well as Management's Discussion and Analysis of Financial Condition and Results of Operations that are included in our Annual Report on Form 10-K for the year ended January 2, 2016, and our other filings, including Current Reports on Form 8-K, that have been filed with the Securities and Exchange Commission (SEC) through the date of this report.

**Overview**

We develop and manufacture high-quality, science-based nutritional and personal care products that are distributed internationally through a network marketing system, which is a form of direct selling. We have chosen this distribution method as we believe it is more conducive to meeting our vision as a company, which is improving the overall health and nutrition of individuals and families around the world. Our customer base comprises two types of customers: Associates and Preferred Customers. Associates share in our company vision by acting as independent distributors of our products in addition to purchasing our products for their personal use. Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. As of October 1, 2016, we had approximately 456,000 active Associates and approximately 94,000 active Preferred Customers worldwide. For purposes of this report, we only count as active customers those Associates and Preferred Customers who have purchased from us at any time during the most recent three-month period.

We have ongoing operations in the following markets, which are grouped and presented as follows:

- Asia Pacific

- Greater China Hong Kong, Taiwan, and China(1)
  
- Southeast Asia Pacific Australia, New Zealand, Singapore, Malaysia, the Philippines, Thailand, and Indonesia(2)
  
- North Asia Japan and South Korea
  
- Americas and Europe United States, Canada, Mexico, Colombia, the United Kingdom, France, Belgium, and the Netherlands

- 
- (1) Our business in China is that of BabyCare, our wholly-owned subsidiary.
  - (2) We commenced operations in Indonesia in the fourth quarter of 2015.

Our primary product lines consist of USANA® Nutritionals, USANA Foods, and Sensé beautiful science® (Sensé), which is our line of personal care products. The USANA Nutritionals product line is further categorized into two separate classifications: Essentials and Optimizers. The following tables summarize the approximate percentage of total product revenue that has been contributed by our major product lines and our top-selling products for the current and prior-year periods as indicated:

Table of Contents

<b>Product Line</b>	<b>Nine Months Ended</b>	
	<b>October 3, 2015</b>	<b>October 1, 2016</b>
<b>USANA® Nutritionals</b>		
Essentials	22%	20%
Optimizers	59%	63%
USANA Foods	12%	10%
Sensé beautiful science®	6%	6%
All Other	1%	1%
<b>Key Product</b>		
USANA® Essentials	14%	14%
Proflavanol®	13%	13%
BiOmega-3	12%	13%

We believe that our ability to attract and retain Associates and Preferred Customers to sell and consume our products is positively influenced by a number of factors, some of which include: the general public's heightened awareness and understanding of the connection between diet and long-term health, and the growing desire for a secondary source of income and small business ownership.

We believe that our high-quality products and our financially rewarding Associate Compensation Plan are the key components to attracting and retaining Associates. We periodically make changes to our Compensation Plan in an effort to ensure that our plan is among the most rewarding in the industry, to encourage behavior that we believe leads to a successful business for our Associates, and to ensure that our plan provides us with leverage to grow sales and earnings.

To further support our Associates in building their businesses, we sponsor meetings and events throughout the year, which offer information about our products and our network marketing system. These meetings are designed to assist Associates in their business development and to provide a forum for interaction with our Associate leaders and members of our management team. We also provide low cost sales tools, including online sales, business management, and training tools, which we believe are an integral part of building and maintaining a successful home-based business for our Associates. Although we provide training and sales tools, we ultimately rely on our Associates to sell our products, attract new customers to purchase our products, and educate and train new Associates.

Because we have operations in multiple markets, with sales and expenses being generated and incurred in multiple currencies, our reported U.S. dollar sales and earnings can be significantly affected by fluctuations in currency exchange rates. In general, our operating results are affected positively by a weakening of the U.S. dollar and negatively by a strengthening of the U.S. dollar. During the nine months ended October 1, 2016, net sales outside of the United States represented 86.6% of consolidated net sales. In our net sales discussions that follow, we approximate the impact of currency fluctuations on net sales by translating current year sales at the average exchange rates in effect during the comparable periods of the prior year.

Table of Contents**Customers**

Because we sell our products exclusively to a customer base of independent Associates and Preferred Customers, to increase net sales we must either increase the number or the productivity of our Associates and Preferred Customers. Increasing the productivity of our Associates and Preferred Customers has not been our primary focus. Rather, we seek to increase the number of Associates and Preferred Customers who use our products. We believe this focus is more consistent with our vision of improving the overall health and nutrition of individuals and families around the world. Sales to Associates account for the majority of our product sales, representing approximately 92% of product sales during the nine months ended October 1, 2016; the remainder of our sales are to Preferred Customers. Increases or decreases in product sales are typically the result of variations in the volume of product sold relating to fluctuations in the number of active Associates and Preferred Customers purchasing our products. The number of active Associates and Preferred Customers is, therefore, used by management as a key non-financial measure.

The tables below summarize the changes in our active customer base by geographic region. These numbers have been rounded to the nearest thousand as of the dates indicated.

<b>Active Associates by Region</b>						
	<b>As of October 3, 2015</b>		<b>As of October 1, 2016</b>		<b>Change from Prior Year</b>	<b>Percent Change</b>
<b>Asia Pacific:</b>						
Greater China	218,000	53.8%	263,000	57.7%	45,000	20.6%
Southeast Asia Pacific	85,000	21.0%	91,000	20.0%	6,000	7.1%
North Asia	13,000	3.2%	15,000	3.3%	2,000	15.4%
Asia Pacific Total	316,000	78.0%	369,000	81.0%	53,000	16.8%
Americas and Europe	89,000	22.0%	87,000	19.0%	(2,000)	(2.2)%
	405,000	100.0%	456,000	100.0%	51,000	12.6%

<b>Active Preferred Customers by Region</b>						
	<b>As of October 3, 2015</b>		<b>As of October 1, 2016</b>		<b>Change from Prior Year</b>	<b>Percent Change</b>
<b>Asia Pacific:</b>						
Greater China	4,000	4.5%	5,000	5.3%	1,000	25.0%
Southeast Asia Pacific	13,000	14.6%	15,000	16.0%	2,000	15.4%
North Asia	9,000	10.1%	10,000	10.6%	1,000	11.1%
Asia Pacific Total	26,000	29.2%	30,000	31.9%	4,000	15.4%
Americas and Europe	63,000	70.8%	64,000	68.1%	1,000	1.6%
	89,000	100.0%	94,000	100.0%	5,000	5.6%

Table of Contents

**Current Focus and Recent Developments**

Our primary objective is to increase the number of Associates and Preferred Customers (referred to together as customers) who use our products throughout the world. We have several strategies in place to support this objective, including:

- Expansion in China, where we plan to continue devoting significant time and resources on growing this market. Our efforts in this regard include transitioning to our new manufacturing and production facility in Beijing, which we anticipate will be fully operational by the end of 2016;
- Enhancing our information technology systems and infrastructure to support our growing customer base and to further improve our customers' experience of doing business with us around the world as well as to prepare for future growth and expansion; and
- Future product and technology innovation that supports our desire to personalize our customers' overall experience with USANA that would encompass our product offering, Associate Compensation Plan, and online business environment;
- Development and offering of market-specific incentives and promotions for our Associates to incent sales and customer growth around the world; and
- Increasing our brand recognition, which includes our relationship as a Trusted Partner and Sponsor of *The Dr. Oz Show*, our sponsorship of the U.S. Ski Team, and our partnership with the Women's Tennis Association; to make it easier for our Associates to talk about USANA with potential customers.

At our 2016 International Convention, we introduced one of the greatest product innovations in our history with the launch of our Incelligence product platform. Incelligence is USANA's proprietary, patent-pending, technology that is designed to support your body's natural ability to nourish, protect and renew itself. As part of our Incelligence platform, we also launched our new flagship multivitamin, CellSentials. Incelligence is a key part of our growth strategy and has already been launched in nine markets around the world with an additional six market launches planned during the remainder of 2016 and into 2017.

**Results of Operations**

*Summary of Financial Results*

Net sales for the third quarter of 2016 increased 9.0% to \$254.2 million, an increase of \$20.9 million, compared with the third quarter of 2015. This increase was driven by higher product sales volume due in great part to strong customer growth. The increase in net sales was driven by 12.6% growth in the number of active Associates and 5.6% growth in the number of Preferred Customers. Associate and customer growth during the quarter was the result of continued momentum in our world-wide business. This increase in net sales during the third quarter of 2016

## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

was partially offset by unfavorable changes in currency exchange rates that reduced net sales for the quarter by \$5.7 million.

Net earnings for the third quarter of 2016 increased 17.5% to \$30.1 million, an increase of \$4.5 million, compared with the third quarter of 2015. The increase in net earnings was driven primarily by a significantly lower effective tax rate, as well as higher net sales, which were largely offset by higher operating expenses during the quarter.



Table of Contents**Quarters Ended October 3, 2015 and October 1, 2016***Net Sales*

The following table summarizes the changes in our net sales by geographic region for the quarters ended as of the dates indicated:

	Net Sales by Region (in thousands)				Change from prior year	Percent change	Currency impact on sales	Percent change excluding currency impact				
	Quarter Ended		Quarter Ended									
	October 3, 2015		October 1, 2016									
Asia Pacific												
Greater China	\$	112,323	48.1%	\$	124,470	49.0%	\$	12,147	10.8%	\$	(6,099)	16.2%
Southeast Asia												
Pacific		45,936	19.7%		54,351	21.4%		8,415	18.3%		988	16.2%
North Asia		9,920	4.3%		11,555	4.5%		1,635	16.5%		626	10.2%
Asia Pacific Total		168,179	72.1%		190,376	74.9%		22,197	13.2%		(4,485)	15.9%
Americas and Europe		65,113	27.9%		63,843	25.1%		(1,270)	(2.0)%		(1,246)	(0.0)%
	\$	233,292	100.0%	\$	254,219	100.0%	\$	20,927	9.0%	\$	(5,731)	11.4%

*Asia Pacific:* The increase in net sales in Greater China continues to be driven by growth in Mainland China, where local currency net sales increased 20.4% and the number of active Associates increased 22.2%. The increase in local currency net sales in Southeast Asia Pacific was driven by Associate growth in several markets, led by Australia and Malaysia. The increase in local currency net sales in North Asia continues to be driven by growth in South Korea, where local currency net sales increased 10.9%. The number of active Associates in South Korea increased 16.7%.

*Americas and Europe:* Net sales in this region was again driven by growth in Mexico, where local currency net sales increased 22.4%. The number of active Associates and Preferred Customers in Mexico increased 16.7% and 12.5%, respectively. Net Sales in the United States decreased \$3.0 million or 8.0%, due to a decline in the number of active customers in this market.

*Gross Profit*

Gross profit decreased 10 basis points to 82.3% of net sales for the third quarter of 2016, from 82.4% in the prior year. This reduction can be attributed to an unfavorable shift in currency exchange rates.

*Associate Incentives*

Associate incentives were 44.4% of net sales for the third quarter of 2016, compared with 43.5% in the third quarter of 2015. This increase can be primarily attributed to higher payout on base commissions and Associate bonus programs. Associate incentives expense has been fairly consistent over the last several quarters and is roughly in-line with our expectations for the remainder of the year.

Table of Contents

*Selling, General and Administrative Expenses*

In absolute terms, our selling, general and administrative expense increased \$7.8 million during the third quarter of 2016 when compared with the same period of the prior year. This increase can be attributed to costs associated with supporting our 2016 strategic initiatives, including (i) higher wages and benefits expense to support our growing customer base and to further improve our customers' experience around the world, (ii) investment in information technology systems and infrastructure, and (iii) increased research and development investment to drive future product and technology innovation.

*Income Taxes*

Income taxes were 16.6% of earnings in the third quarter of 2016 compared with 33.3% of earnings in the third quarter of 2015. The primary reason for the year-over-year effective tax rate improvement was due to the early adoption of ASU 2016-09 Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which requires excess tax benefits or tax deficiencies resulting from exercise or settlement of share-based payment transactions to be recognized as an income tax benefit or expense in the income statement prospectively.

*Diluted Earnings Per Share*

Diluted earnings per share increased 25.0% in the third quarter of 2016 when compared with the prior year quarter. This increase was mostly due to a lower effective tax rate, primarily resulting from the adoption of ASU 2016-09 that contributed \$0.50 to the quarter, and a lower number of shares outstanding resulting from activity under our share buyback program.

Table of Contents**Nine Months Ended October 3, 2015 and October 1, 2016***Net Sales*

The following table summarizes the changes in our net sales by geographic region for the periods ended as of the dates indicated:

	Net Sales by Region (in thousands) Nine Months Ended				Change from prior year	Percent change	Currency impact on sales	Percent change excluding currency impact				
	October 3, 2015		October 1, 2016									
Asia Pacific												
Greater China	\$	325,942	47.5%	\$	373,308	49.6%	\$	47,366	14.5%	\$	(18,066)	20.1%
Southeast Asia Pacific		137,308	20.0%		154,335	20.5%		17,027	12.4%		(5,512)	16.4%
North Asia		29,495	4.3%		33,376	4.4%		3,881	13.2%		(690)	15.5%
Asia Pacific Total		492,745	71.8%		561,019	74.5%		68,274	13.9%		(24,268)	18.8%
Americas and Europe		193,169	28.2%		192,163	25.5%		(1,006)	(0.5)%		(8,159)	3.7%
	\$	685,914	100.0%	\$	753,182	100.0%	\$	67,268	9.8%	\$	(32,427)	14.5%

*Asia Pacific:* The increase in net sales in Greater China continues to be driven by growth in Mainland China, where local currency net sales increased 25.1% and the number of active Associates increased 22.2%. The increase in local currency net sales in Southeast Asia Pacific was driven by double-digit sales growth in many of our markets led by Thailand, Malaysia, Australia, and New Zealand. This increase was the result of growth in the average number of active Associates and Preferred Customers purchasing our products during the first nine months of the year. The increase in local currency net sales in North Asia continues to be driven by growth in South Korea, where local currency net sales increased 17.1%.

*Americas and Europe:* The increase in local currency net sales in this region was driven by growth in Mexico and Canada, where local currency net sales increased 21.6% and 13.3%, respectively. Net Sales in the United States declined 5.5% due to a decline in the number of active customers in this market.

*Gross Profit*

Gross profit decreased to 82.2% of net sales for the first nine months of 2016, from 82.6% in the comparable prior year period. This reduction can primarily be attributed to an unfavorable shift in currency exchange rates. This reduction was partially offset by a favorable shift in sales mix by market and to a lesser extent by modest price adjustments that we implemented during the first half of the year.

*Associate Incentives*

Associate incentives were 44.5% of net sales for the first nine months of 2016, compared with 44.4% in the comparable prior year period. This increase can primarily be attributed to increased spending on contests and promotions, and by modest price adjustments that we implemented during the first half of the year.

Table of Contents

*Selling, General and Administrative Expenses*

In absolute terms, our selling, general and administrative expense increased \$21.8 million during the first nine months of 2016 when compared with the same period of the prior year. This increase can be attributed to costs associated with supporting our 2016 strategic initiatives, including (i) higher wages and benefits expense to support our growing customer base and to further improve our customers' experience around the world, (ii) investment in information technology systems and infrastructure, (iii) continued investment in Mainland China, and (iv) increased research and development investment to drive future product and technology innovation.

*Income Taxes*

Income taxes were 26.8% of earnings for the first nine months of 2016 compared with 34.0% of earnings in the first nine months of 2015. The primary reason for the year-over-year effective tax rate improvement was due to the early adoption of ASU 2016-09 Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which requires excess tax benefits or tax deficiencies resulting from exercise or settlement of share-based payment transactions to be recognized as an income tax benefit or expense in the income statement prospectively.

*Diluted Earnings Per Share*

Diluted earnings per share increased 16.6% in the first nine months of 2016 when compared with the prior year period. This increase was mostly due to a lower effective tax rate, primarily resulting from the adoption of ASU 2016-09 that contributed \$0.52 year-to-date, and due to a lower number of shares outstanding resulting from activity under our share buyback program.

**Liquidity and Capital Resources**

We have historically met our working capital and capital expenditure requirements by using both net cash flow from operations and by drawing from our line of credit. Our principal source of liquidity is our operating cash flow. Although we are required to maintain cash deposits with banks in certain of our markets, there are currently no material restrictions on our ability to transfer and remit funds among our international markets. Notwithstanding the foregoing, if we were to repatriate the \$18.2 million of cumulative earnings that have been indefinitely reinvested in certain of our markets at October 1, 2016, there would be a tax liability to the Company of approximately \$3.1 million.

We have historically generated positive cash flow due to our strong operating margins. Net cash flow from operating activities totaled \$81.7 million in the first nine months of 2016. Items increasing cash flows from operations in the first nine months of 2016 are higher net earnings, which were increased by \$7.3 million from the adoption of ASU 2016-09, and adjusted for higher equity based compensation expense, and depreciation and amortization, reduced by employee compensation costs, and taxes payable.

## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Net cash flow from operating activities totaled \$74.5 million in the first nine months of 2015. Items increasing cash flows from operations in the first nine months of 2015 were higher net earnings, accrued incentives and deferred revenue, and taxes payable, reduced by inventory and employee compensation costs.

Cash and cash equivalents decreased to \$134.5 million at October 1, 2016, from \$143.2 million at January 2, 2016. Of the \$134.5 million held at October 1, 2016, \$13.0 million was held in the United States and \$121.5 million was held by international subsidiaries. Of the \$143.2 million in cash and cash equivalents held at January 2, 2016, \$16.2 million was held in the United States and \$127.0 million was held by international subsidiaries. Net working capital increased to \$119.7 million at October 1, 2016, from \$112.9 million at January 2, 2016.

Our new state-of-the-art manufacturing and production facility in China is expected to become fully operational by the end of 2016. During the third quarter of 2016, we obtained the necessary permits and product registrations to begin production in the new facility.

Table of Contents

Beginning in 2013, we extended non-revolving credit to the supplier of our nutrition bars to allow this supplier to modify its facility and acquire the necessary equipment to manufacture our bars. Notes receivable from this supplier as of January 2, 2016 and October 1, 2016, were \$8.3 million and \$7.1 million, respectively, and are included as non-current other assets on the balance sheet.

*Line of credit*

We have a long-standing relationship with Bank of America. We currently maintain a \$75.0 million credit facility pursuant to an Amended and Restated Credit Agreement ( *Credit Agreement* ) with the bank. On February 19, 2016 we entered into a Second Amendment ( *Amendment* ) to our Credit Agreement, which among other things, extends the term of the Credit Agreement to April 27, 2021. The Amendment also increases the amount we may borrow under the Credit Agreement from \$75.0 million to up to \$125.0 million through October 31, 2016. On November 1, 2016 the amount we may borrow under the Credit Agreement will revert to \$75.0 million for the term of the agreement. The Amendment also increases our consolidated rolling four-quarter adjusted earnings before interest, taxes, depreciation and amortization ( *adjusted EBITDA* ) covenant from \$60.0 million to equal to or greater than \$100.0 million.

Bank guarantees are considered a reduction of the overall availability of credit. As of October 1, 2016, such normal course of business bank guarantees reduced our available borrowing limit by \$5.1 million. During the first nine months, we utilized our credit facility, and as of October 1, 2016, we had a balance of \$1.2 million outstanding.

The Credit Agreement for this credit facility contains restrictive covenants, which require us to maintain a consolidated rolling four-quarter adjusted earnings before interest, taxes, depreciation and amortization ( *adjusted EBITDA* ) equal to or greater than \$100.0 million (increased by the Amendment from \$60.0 million), and a ratio of consolidated funded debt to adjusted EBITDA of 2.0 to 1.0 at the end of each quarter. The adjusted EBITDA under this agreement is modified for certain non-cash expenses. As of October 1, 2016, we were in compliance with these covenants. Management is not aware of any issues currently impacting Bank of America's ability to honor their commitment to extend credit under this facility.

*Share repurchase*

We have a share repurchase plan that has been ongoing since the fourth quarter of 2000. The objective of this plan is to return value to our shareholders. Our Board of Directors has periodically approved additional dollar amounts for share repurchases under that plan. Share repurchases are made from time-to-time, in the open market, through block trades or otherwise, and are based on market conditions, the level of our cash balances, general business opportunities, and other factors. During the nine months ended October 1, 2016, we repurchased 553,082 shares of common stock for a total investment of \$64.6 million, at an average market price of \$116.82 per share pursuant to a preset trading plan meeting the requirements of a Rule 10b5-1 under the Securities Exchange Act of 1934 as amended. As of October 1, 2016, the remaining approved repurchase amount under the plan was \$35.4 million. There is currently no expiration date on the remaining approved repurchase amount and no requirement for future share repurchases.

*Summary*



## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

We believe that current cash balances, future cash provided by operations, and amounts available under our line of credit will be sufficient to cover our operating and capital needs in the ordinary course of business for the foreseeable future. If we experience an adverse operating environment or unanticipated and unusual capital expenditure requirements, additional financing may be required. No assurance can be given, however, that additional financing, if required, would be available at all or on favorable terms. We might also require or seek additional financing for the purpose of expanding into new markets, growing our existing markets, or for other reasons. Such financing may include the use of additional debt or the sale of additional equity securities. Any financing which involves the sale of equity securities or instruments that are convertible into equity securities could result in immediate and possibly significant dilution to our existing shareholders.

Table of Contents

**Forward-Looking Statements and Certain Risks**

The statements contained in this report that are not purely historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934 (the Exchange Act). These statements represent our expectations, hopes, beliefs, anticipations, commitments, intentions, and strategies regarding the future. They may be identified by the use of words or phrases such as believes, expects, anticipates, should, plans, estimates, and potential, among others. Forward-looking statements include, but are not limited to, statements contained in Management's Discussion and Analysis of Financial Condition and Results of Operations regarding our financial performance, revenue, and expense levels in the future and the sufficiency of our existing assets to fund our future operations and capital spending needs. Readers are cautioned that actual results could differ materially from the anticipated results or other expectations that are expressed in these forward-looking statements for the reasons that are detailed in our most recent Annual Report on Form 10-K. The fact that some of these risk factors may be the same or similar to those in our past SEC reports means only that the risks are present in multiple periods. We believe that many of the risks detailed here and in our other SEC filings are part of doing business in the industry in which we operate and will likely be present in all periods reported. The fact that certain risks are common in the industry does not lessen their significance. The forward-looking statements contained in this report are made as of the date of this report, and we assume no obligation to update them or to update the reasons why our actual results could differ from those that we have projected. Among others, risks and uncertainties that may affect our business, financial condition, performance, development, and results of operations include:

- Our ability to attract and maintain a sufficient number of Associates;
  
- Our dependence upon a network marketing system to distribute our products and the activities of our independent Associates;
  
- The expansion of our business in China through BabyCare;
  
- Unanticipated effects of changes to our Compensation Plan;
  
- Our planned expansion into international markets, including delays in commencement of sales or product offerings in any new market, delays in compliance with local marketing or other regulatory requirements, or changes in target markets;
  
- General economic conditions, both domestically and internationally;
  
- Potential political events, natural disasters, or other events that may negatively affect economic conditions;

- Potential effects of adverse publicity regarding the Company, nutritional supplements, or the network marketing industry;
- Reliance on key management personnel;
- Extensive government regulation of the Company's products, manufacturing, and network marketing system;
- Potential inability to sustain or manage growth, including the failure to continue to develop new products;
- An increase in the amount of Associate incentives;
- Our reliance on the use of information technology;
- The effects of competition from new and established network and direct selling organizations in our key markets;
- The adverse effect of the loss of a high-level sponsoring Associate, together with a group of leading Associates, in that person's downline;
- The loss of product market share or Associates to competitors;
- Potential adverse effects of customs, duties, taxation, and transfer pricing regulations, including regulations governing distinctions between and Company responsibilities to employees and independent contractors;
- The fluctuation in the value of foreign currencies against the U.S. dollar;
- Our reliance on outside suppliers for raw materials and certain manufactured items;



Table of Contents

- Shortages of raw materials that we use in certain of our products;
- Significant price increases of our key raw materials;
- Product liability claims and other risks that may arise with our manufacturing activity;
- Intellectual property risks;
- Liability claims that may arise with our Athlete Guarantee program;
- Continued compliance with debt covenants;
- Disruptions to shipping channels that are used to distribute our products to international warehouses;
- The introduction of new laws or changes to existing laws, both domestically and internationally; and
- The outcome of regulatory and litigation matters.

**Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

There have been no material changes from the information presented for the year ended January 2, 2016.

**Item 4. CONTROLS AND PROCEDURES**

**Disclosure Controls and Procedures**

We maintain disclosure controls and procedures that are designed to ensure that information that is required to be disclosed in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods that are specified in the SEC's rules and forms and that such information is accumulated and communicated to management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding any required disclosure. In designing and evaluating these disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

As of the end of the period covered by this report, our Principal Executive Officer and Principal Financial Officer evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Based on this evaluation, the Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective as of October 1, 2016.

#### **Changes in Internal Control Over Financial Reporting**

There were no changes in our internal control over financial reporting that occurred during the quarter ended October 1, 2016, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## **PART II. OTHER INFORMATION**

### **Item 5. Other Information**

On October 25, 2016, the Company's Board of Directors approved a two-for-one split of common stock in the form of a stock dividend. The stock dividend will be distributed on November 22, 2016 to shareholders of record as of November 14, 2016. The dividend distribution will double the number of shares outstanding; however, it will not affect the number of authorized shares of the Company or the par value of the common stock. The announcement regarding the two-for-one stock split was included in a Current Report on Form 8-K, filed by the Company on October 25, 2016.

Table of Contents

**Item 6. EXHIBITS**

Exhibit Number	Description
3.1	Amended and Restated Articles of Incorporation (incorporated by reference to Current Report on Form 8-K, filed April 25, 2006)
3.2	Bylaws (incorporated by reference to Current Report on Form 8-K, filed April 25, 2006)
4.1	Specimen Stock Certificate for Common Stock (incorporated by reference to Registration Statement on Form 10, File No. 0-21116, effective April 16, 1993)
10.1	USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (incorporated by reference to Current Report on Form 8-K, filed April 25, 2006)*
10.2	Form of Stock Option Agreement for award of non-statutory stock options to employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (incorporated by reference to Current Report on Form 8-K, filed April 26, 2006)*
10.3	Form of Stock Option Agreement for award of non-statutory stock options to directors who are not employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (incorporated by reference to Current Report on Form 8-K, filed April 26, 2006)*
10.4	Form of Incentive Stock Option Agreement for award of incentive stock options to employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (incorporated by reference to Current Report on Form 8-K, filed April 26, 2006)*
10.5	Form of Stock-Settled Stock Appreciation Rights Award Agreement for award of stock-settled stock appreciation rights to employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (incorporated by reference to Current Report on Form 8-K, filed April 26, 2006)*
10.6	Form of Stock-Settled Stock Appreciation Rights Award Agreement for award of stock-settled stock appreciation rights to directors who are not employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (incorporated by reference to Current Report on Form 8-K, filed April 26, 2006)*
10.7	Form of Deferred Stock Unit Award Agreement for grants of deferred stock units to directors who are not employees under the USANA Health Sciences, Inc. 2006 Equity Incentive Award Plan (incorporated by reference to Current Report on Form 8-K, filed April 26, 2006)*
10.8	Form of Indemnification Agreement between the Company and its directors (incorporated by reference to Current Report on Form 8-K, filed May 24, 2006)*
10.9	Form of Indemnification Agreement between the Company and certain of its officers (Incorporated by reference to Report on Form 8-K, filed May 24, 2006)*
10.10	Share Purchase Agreement, dated as of August 16, 2010, among USANA Health Sciences, Inc., Petlane, Inc., Yaolan Ltd., and BabyCare Holdings Ltd. (Incorporated by Reference to Report on Form 8-K, filed August 16, 2010)
10.11	Amended and Restated Credit Agreement, dated as of April 27, 2011 (Incorporated by reference to Report on Form 8-K, filed April 28, 2011)
10.12	Form of Executive Confidentiality, Non-Disclosure and Non-Solicitation Agreement (incorporated by reference to Quarterly Report on Form 10-Q for the period ended October 1, 2011, filed November 9, 2011)*
10.13	

Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

Separation and Release of Claims Agreement dated as of December 21, 2012 by and between USANA Health Sciences, Inc. and Roy Truett (incorporated by reference to Report on Form 8-K/A, filed December 26, 2012)\*



## Edgar Filing: USANA HEALTH SCIENCES INC - Form 10-Q

### Table of Contents

10.14	Amendment to Confidentiality, Non-Disclosure and Non-Solicitation Agreement dated as of December 21, 2012 by and between USANA Health Sciences, Inc. and Roy Truett (incorporated by reference to Report on Form 8-K/A, filed December 26, 2012)*
10.15	Amendment to Amended and Restated Credit Agreement, dated as of July 18, 2013 (Incorporated by reference to Report on Form 8-K, filed July 23, 2013)
10.16	USANA Health Sciences, Inc. 2015 Equity Incentive Award Plan (incorporated by reference to Report on Form 8-K, filed July 31, 2015)
10.17	Form of Stock-Settled Stock Appreciation Rights Award Agreement for employees under the USANA Health Sciences, Inc. 2015 Equity Incentive Award Plan (incorporated by reference to Report on Form 8-K, filed July 31, 2015)*
10.18	Form of Stock-Settled Stock Appreciation Rights Award Agreement for non-employee directors under the USANA Health Sciences, Inc. 2015 Equity Incentive Award Plan (incorporated by reference to Report on Form 8-K, filed July 31, 2015)*
10.19	Form of Restricted Stock Unit Award Agreement for employees under the USANA Health Sciences, Inc. 2015 Equity Incentive Award Plan (incorporated by reference to Report on Form 8-K, filed July 31, 2015)*
10.20	Form of Restricted Stock Unit Award Agreement for non-employee directors under the USANA Health Sciences, Inc. 2015 Equity Incentive Award Plan (incorporated by reference to Report on Form 8-K, filed July 31, 2015)
10.21	Form of Deferred Stock Unit Award Agreement for grants of deferred stock units to non-employee director under the USANA Health Sciences, Inc. 2015 Equity Incentive Award Plan (incorporated by reference to Report on Form 8-K, filed July 31, 2015)
10.22	Second Amendment to the Amended and Restated Credit Agreement and Amendment to loan documents (incorporated by reference to Report on Form 8-K, filed February 23, 2016)
31.1	Certification of Principal Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
31.2	Certification of Principal Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
32.1	Certification of Principal Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350 (filed herewith)
32.2	Certification of Principal Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350 (filed herewith)
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

---

\* Denotes a management contract or compensatory plan or arrangement.



Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

USANA HEALTH SCIENCES, INC.

Date: November 9, 2016

/s/ Paul A. Jones  
Paul A. Jones  
Principal Financial and Accounting Officer